Evidence map›Paper›PMID 21454801›Full record

ArticleAmerican journal of respiratory cell and molecular biology2011

An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.

Arti Shukla, Trisha F Barrett, Maximilian B MacPherson, Jedd M Hillegass, Naomi K Fukagawa, William A Swain, Kenneth J O'Byrne, Joseph R Testa, Harvey I Pass, Stephen P Faux and 1 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Malignant mesothelioma: development to therapy.Journal of cellular biochemistry · 2014
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Arti ShuklaDepartment of Pathology, University of Vermont College of Medicine, Burlington, 05405, USA.
Trisha F Barrett
Maximilian B MacPherson
Jedd M Hillegass
Naomi K Fukagawa
William A Swain
Kenneth J O'Byrne
Joseph R Testa
Harvey I Pass
Stephen P Faux
Brooke T Mossman
University of Vermont · USUniversity of Leicester · GBFox Chase Cancer Center · USNYU Langone Health · USSt. James's Hospital · IE

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
VOLATILE SIGNALING IN PHARBITIS NILP20RR016462 · NCRR · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI KIRSHENBAUM, ARI PHILLIP · 2001 to 2011
$31.1M
PATHOLOGY, VIROLOGY, AND ANIMAL COREP01CA114047 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2006 to 2010
$8.0M
Role of Cell Mediators in Asbestos-SV40 CarcinogenesisR01CA106567 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2005 to 2009
$1.3M
NCI NIH HHS CA-06927NCI NIH HHS P01 CA114047NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA106567NCRR NIH HHS P20 RR016462
6 · The paper itself

Abstract

We hypothesized that normal human mesothelial cells acquire resistance to asbestos-induced toxicity via induction of one or more epidermal growth factor receptor (EGFR)-linked survival pathways (phosphoinositol-3-kinase/AKT/mammalian target of rapamycin and extracellular signal-regulated kinase [ERK] 1/2) during simian virus 40 (SV40) transformation and carcinogenesis. Both isolated HKNM-2 mesothelial cells and a telomerase-immortalized mesothelial line (LP9/TERT-1) were more sensitive to crocidolite asbestos toxicity than an SV40 Tag-immortalized mesothelial line (MET5A) and malignant mesothelioma cell lines (HMESO and PPM Mill). Whereas increases in phosphorylation of AKT (pAKT) were observed in MET5A cells in response to asbestos, LP9/TERT-1 cells exhibited dose-related decreases in pAKT levels. Pretreatment with an EGFR phosphorylation or mitogen-activated protein kinase kinase 1/2 inhibitor abrogated asbestos-induced phosphorylated ERK (pERK) 1/2 levels in both LP9/TERT-1 and MET5A cells as well as increases in pAKT levels in MET5A cells. Transient transfection of small interfering RNAs targeting ERK1, ERK2, or AKT revealed that ERK1/2 pathways were involved in cell death by asbestos in both cell lines. Asbestos-resistant HMESO or PPM Mill cells with high endogenous levels of ERKs or AKT did not show dose-responsive increases in pERK1/ERK1, pERK2/ERK2, or pAKT/AKT levels by asbestos. However, small hairpin ERK2 stable cell lines created from both malignant mesothelioma lines were more sensitive to asbestos toxicity than shERK1 and shControl lines, and exhibited unique, tumor-specific changes in endogenous cell death-related gene expression. Our results suggest that EGFR phosphorylation is causally linked to pERK and pAKT activation by asbestos in normal and SV40 Tag-immortalized human mesothelial cells. They also indicate that ERK2 plays a role in modulating asbestos toxicity by regulating genes critical to cell injury and survival that are differentially expressed in human mesotheliomas.

Indexed as

Asbestos, CrocidoliteCell LineCell SurvivalEnzyme InhibitorsErbB ReceptorsGene ExpressionHumansMAP Kinase Kinase 1MAP Kinase Kinase 2MesotheliomaMitogen-Activated Protein Kinase 1Pleural NeoplasmsRNA, Small InterferingSignal TransductionAsbestos, CrocidoliteEnzyme InhibitorsErbB ReceptorsMAP2K1 protein, humanMAP2K2 protein, humanMAPK1 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2Mitogen-Activated Protein Kinase 1RNA, Small Interfering

Identifiers

PMID21454801
PMCPMC3262687
OpenAlexW2090354536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.